Skip to main content
NVDA-0.08%AAPL+0.03%MSFT+0.34%GOOGL+1.19%AMZN+0.29%TSM+2.95%SPCX+1.14%AVGO+4.00%TSLA+0.05%META-0.10%LLY+0.22%BRK-B-1.02%MU-0.26%SKHY+1.92%WMT-0.81%AMD+5.45%JPM+0.52%V-0.57%XOM-2.53%JNJ+0.91%ASMLa+2.80%MA-0.59%ABBV-0.10%INTC+3.61%1398.HK+2.15%CVX-1.59%0700.HK-0.31%CSCO+1.03%COST-1.30%ORCL+3.55%KO-1.64%UNH-0.08%PG-0.45%BAC+0.32%1816.HK+1.32%3988.HK+0.66%CAT+3.06%DELL+7.38%HD-0.28%PM+0.37%0857.HK-0.98%AMAT+2.15%AP2d+2.18%0939.HK+0.81%GE+3.20%1288.HK+0.60%LRCX+1.41%NVS+1.98%0005.HK-5.56%MS+1.91%USDJPY+0.69%EURUSD-0.64%AUDJPY+0.59%EURAUD-0.53%GBPUSD-0.51%USDCHF+0.46%NZDJPY+0.42%GBPTRY+0.41%GBPAUD-0.40%CADJPY+0.40%EURNZD-0.38%AUDCHF+0.37%GBPHKD+0.32%EURCAD-0.31%USDCAD+0.31%GBPMXN-0.28%USDTRY+0.28%NZDUSD-0.27%CHFJPY+0.25%GBPNZD-0.23%GBPCAD-0.21%AUDCAD+0.20%EURCHF-0.20%NZDCHF+0.19%GBPJPY+0.18%USDILS+0.16%AUDNZD+0.16%CADCHF+0.15%EURGBP-0.13%AUDUSD-0.11%EURJPY+0.07%NZDMXN+0.06%GBPCHF-0.06%NZDSGD+0.06%EURSGD+0.06%CHFSGD+0.05%USDCOP-0.04%USDCNH-0.04%USDHKD+0.03%NZDCAD+0.03%USDTHB-0.03%AUDSGD+0.03%USDSGD-0.01%USDZAR0.00%GBPSGD0.00%USDMXN0.00%SGDJPY0.00%USDSEK0.00%USDPLN0.00%USDDKK0.00%EURHKD0.00%EURCZK0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSEK0.00%AUDDKK0.00%CHFSEK0.00%GBPZAR0.00%EURNOK0.00%PLNJPY0.00%EURDKK0.00%USDNOK0.00%EURPLN0.00%CHFNOK0.00%NOKJPY0.00%USOIL-0.39%XNGUSD+0.32%XPTUSD+0.17%XAGUSD+0.13%GAGUSD+0.13%XAUUSD+0.09%GAUUSD+0.09%HG1-0.02%S10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.04%ETHUSD+23.96%USDTUSD+0.05%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.82%ZECUSDT+6.31%DOGEUSD+20.65%XMRUSDT+1.57%LINKUSD+25.58%BCHUSDT+3.83%XLMUSD+0.53%UNIUSD-0.92%LTCUSD+17.89%SUIUSD+1.18%HBARUSDT-1.48%TONUSD+41.71%TAOUSDT+1.41%AAVEUSD-2.43%DOTUSDT-1.09%ICPUSDT-1.71%ONDOUSDT+0.80%WLDUSDT+0.14%ARBUSDT-1.18%JUPUSDT+0.66%INJUSDT-1.32%ATOMUSDT-1.19%STXUSDT-1.08%TIAUSDT-1.79%PYTHUSDT-2.78%FETUSDT+3.93%SEIUSDT+0.54%IMXUSDT-0.66%GRTUSDT+0.86%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+0.50%POLUSDT+0.99%AXSUSDT+0.83%EOSUSDT+1.14%FARTCOINUSDT+2.28%DYDXUSDT+2.47%GALAUSDT+1.56%ORDIUSDT+2.62%RONINUSDT+1.89%NOTUSDT+1.92%NVDA-0.08%AAPL+0.03%MSFT+0.34%GOOGL+1.19%AMZN+0.29%TSM+2.95%SPCX+1.14%AVGO+4.00%TSLA+0.05%META-0.10%LLY+0.22%BRK-B-1.02%MU-0.26%SKHY+1.92%WMT-0.81%AMD+5.45%JPM+0.52%V-0.57%XOM-2.53%JNJ+0.91%ASMLa+2.80%MA-0.59%ABBV-0.10%INTC+3.61%1398.HK+2.15%CVX-1.59%0700.HK-0.31%CSCO+1.03%COST-1.30%ORCL+3.55%KO-1.64%UNH-0.08%PG-0.45%BAC+0.32%1816.HK+1.32%3988.HK+0.66%CAT+3.06%DELL+7.38%HD-0.28%PM+0.37%0857.HK-0.98%AMAT+2.15%AP2d+2.18%0939.HK+0.81%GE+3.20%1288.HK+0.60%LRCX+1.41%NVS+1.98%0005.HK-5.56%MS+1.91%USDJPY+0.69%EURUSD-0.64%AUDJPY+0.59%EURAUD-0.53%GBPUSD-0.51%USDCHF+0.46%NZDJPY+0.42%GBPTRY+0.41%GBPAUD-0.40%CADJPY+0.40%EURNZD-0.38%AUDCHF+0.37%GBPHKD+0.32%EURCAD-0.31%USDCAD+0.31%GBPMXN-0.28%USDTRY+0.28%NZDUSD-0.27%CHFJPY+0.25%GBPNZD-0.23%GBPCAD-0.21%AUDCAD+0.20%EURCHF-0.20%NZDCHF+0.19%GBPJPY+0.18%USDILS+0.16%AUDNZD+0.16%CADCHF+0.15%EURGBP-0.13%AUDUSD-0.11%EURJPY+0.07%NZDMXN+0.06%GBPCHF-0.06%NZDSGD+0.06%EURSGD+0.06%CHFSGD+0.05%USDCOP-0.04%USDCNH-0.04%USDHKD+0.03%NZDCAD+0.03%USDTHB-0.03%AUDSGD+0.03%USDSGD-0.01%USDZAR0.00%GBPSGD0.00%USDMXN0.00%SGDJPY0.00%USDSEK0.00%USDPLN0.00%USDDKK0.00%EURHKD0.00%EURCZK0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSEK0.00%AUDDKK0.00%CHFSEK0.00%GBPZAR0.00%EURNOK0.00%PLNJPY0.00%EURDKK0.00%USDNOK0.00%EURPLN0.00%CHFNOK0.00%NOKJPY0.00%USOIL-0.39%XNGUSD+0.32%XPTUSD+0.17%XAGUSD+0.13%GAGUSD+0.13%XAUUSD+0.09%GAUUSD+0.09%HG1-0.02%S10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.04%ETHUSD+23.96%USDTUSD+0.05%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.82%ZECUSDT+6.31%DOGEUSD+20.65%XMRUSDT+1.57%LINKUSD+25.58%BCHUSDT+3.83%XLMUSD+0.53%UNIUSD-0.92%LTCUSD+17.89%SUIUSD+1.18%HBARUSDT-1.48%TONUSD+41.71%TAOUSDT+1.41%AAVEUSD-2.43%DOTUSDT-1.09%ICPUSDT-1.71%ONDOUSDT+0.80%WLDUSDT+0.14%ARBUSDT-1.18%JUPUSDT+0.66%INJUSDT-1.32%ATOMUSDT-1.19%STXUSDT-1.08%TIAUSDT-1.79%PYTHUSDT-2.78%FETUSDT+3.93%SEIUSDT+0.54%IMXUSDT-0.66%GRTUSDT+0.86%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+0.50%POLUSDT+0.99%AXSUSDT+0.83%EOSUSDT+1.14%FARTCOINUSDT+2.28%DYDXUSDT+2.47%GALAUSDT+1.56%ORDIUSDT+2.62%RONINUSDT+1.89%NOTUSDT+1.92%
AP

Atea Pharmaceuticals, Inc. (AVIR)

NASDAQ • Healthcare

$4.17
+$0 (+0.2%)
Market closed

Last close at October 27, 2026 at 20:00 UTC

Open$4.14
Day Range$4.05 - $4.29
Avg. Volume (3M)298.6K
Market Cap$334.4M
52 Week Range
$2.87$6.45
Next EarningsIn 15 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$165.2M
EPS (TTM)
-$2.08
ROA (TTM)
-71.16%
Current Ratio
8.13

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-16.3%Q1 2026-$0.57
+5.0%Q2 2026-$0.57
+26.1%Q3 2026-$0.41
Next

Nov 11

in 15 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +26.1%

Atea Pharmaceuticals’ preliminary results showed EPS of -$0.41 topping the -$0.56 estimate by $0.15 for the second fiscal quarter of 2026, reported August 12, 2026, alongside a net loss that narrowed year over year. Net income was a loss of about $32.9 million, up ~11% from a loss of roughly $37.2 million a year ago, while operating income came in at a loss of about $35.1 million. On a per-share basis, EPS improved ~7% from -$0.44 a year ago. The company generated negative operating cash flow of about $37.1 million during the quarter. Atea remains focused on advancing its antiviral pipeline, including bemnifosbuvir and ruzasvir programs in hepatitis C. For the next period, consensus calls for EPS of -$0.51 on revenue of $50.4 million.

Next report — what to expect

Atea Pharmaceuticals, Inc. (AVIR) is set to report on November 11, 2026. Wall Street’s next-period consensus calls for EPS of -$0.51 on revenue of $50.4 million. In recent history, the company has beaten EPS in 5 of its 8 most recent quarters, a key point to watch against expectations.

View full earnings history

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company developing oral antiviral therapeutics for patients with serious viral infections. In qualitative terms, it is a clinical-stage biotech business rather than a commercialized drug maker, with its work centered on advancing liver-focused antiviral candidates through human trials.

Name
Atea Pharmaceuticals, Inc.
CEO
Jean-Pierre Sommadossi
Website
www.ateapharma.com
Industry
Healthcare
Year Founded
2012
Employees
55

Today's Snapshot

AI-generated

AVIR ended the day slightly higher at 4.17, in line with a flat sector.

Trading Volume

Below 10d avg (327.6K)

245.2K

vs S&P 500 Today

Moderate Underperformance

-0.45%

Updated: October 27, 2026 at 20:18 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
AVIR is exhibiting clear weakness as the stock trades around 4.17 while trend strength remains meaningful — ADX near 32.6 — indicating a decisive trend rather than sideways noise. Momentum and trend-following indicators are negative with a selling MACD and below‑average short moving averages versus the 200‑day, and the RSI sits near the low‑30 range, showing limited upside momentum. Volatility is elevated with an ATR equal to roughly 5.7% of price, and on‑balance measures point to net distribution, all of which underpins the bearish tilt. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$4.32 - $4.90
    Sell
  • RSI (14)30.81
    Neutral
  • Stochastic %K (14, 3, 3)14.87
    Buy
  • MACD Level (12, 26)-0.30
    Sell

Peers & Related Assets

VIRVir Biotechnology, Inc.
$11.57+4.8%
ABUSArbutus Biopharma Corp
$4.29+2.1%
ENTAEnanta Pharmaceuticals, Inc.
$12.18+1.5%
ASMBAssembly Biosciences, Inc.
ALGSAligos Therapeutics, Inc.
COCPCocrystal Pharma, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.